Jade Biosciences Prices 10M Shares at $15 to Raise $150M
JBIO•Jade Biosciences is offering 10 million shares of common stock at $15 per share to raise $150 million in gross proceeds, with underwriters granted a 30-day option to purchase up to 1.5 million additional shares. Proceeds will fund clinical trials, manufacturing, R&D and working capital for its autoimmune pipeline.
1. Offering Details
Jade Biosciences announced pricing of a public offering of 10 million common shares at $15.00 per share, generating $150.0 million in gross proceeds before underwriting discounts and commissions.
2. Underwriter Overallotment Option
The company granted the underwriters a 30-day option to purchase an additional 1.5 million shares at the public offering price less underwriting discounts and commissions.
3. Use of Proceeds
Net proceeds, together with existing cash and investments, will support clinical trials, preclinical studies, manufacturing, research and development, capital expenditures and working capital for its autoimmune therapy programs.
4. Closing Timeline and Registration
The offering is slated to close on June 5, 2026, subject to customary closing conditions, under a shelf registration statement declared effective May 15, 2026.
